UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 197

Sortiert nach

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

Therapeutic Advances in Medical Oncology, 2016-09, Vol.8 (5), p.339-350

Chan, Arlene

2016

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer bone metastases: pathogenesis and therapeutic targets

The international journal of biochemistry & cell biology, 2018-03, Vol.96, p.63-78

2018

Link zum Volltext

Verfügbarkeit prüfen

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1719-1725

2013

Link zum Volltext

Verfügbarkeit prüfen

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2016-03, Vol.17 (3), p.367-377

2016

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

The New England journal of medicine, 2006-12, Vol.355 (26), p.2733-2743

2006

Link zum Volltext

Verfügbarkeit prüfen

HER2 positive metastatic breast cancer: What happens after first line failure?

Cancer forum, 2016-11, Vol.40 (3), p.29-31

Arlene Chan

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Journal of clinical oncology, 2010-07, Vol.28 (20), p.3239-3247

2010

Link zum Volltext

Verfügbarkeit prüfen

The role of pigment epithelium-derived factor in protecting against cellular stress

Free radical research, 2019-12, Vol.53 (11-12), p.1166-1180

2019

Link zum Volltext

Verfügbarkeit prüfen

NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer

International journal of molecular sciences, 2022-12, Vol.23 (24), p.15641

2022

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2586-2592

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of clinical oncology, 2013-01, Vol.31 (2), p.195-202

2013

Link zum Volltext

Verfügbarkeit prüfen

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Journal of clinical oncology, 2012-03, Vol.30 (9), p.921-929

2012

Link zum Volltext

Verfügbarkeit prüfen

Contralateral Breast Cancer: Influence Of Molecular Subtype, Clinical Features And Treatment Given In A Single Institution Study

Breast (Edinburgh), 2023-04, Vol.68, p.239-240

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial

Journal of clinical oncology, 2011-10, Vol.29 (29), p.3877-3884

2011

Link zum Volltext

Verfügbarkeit prüfen

Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada

PloS one, 2021-03, Vol.16 (3), p.e0248626-e0248626

2021

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Breast (Edinburgh), 2020-12, Vol.54, p.148-154

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic role of immune environment in luminal B early breast cancer

Cancer medicine (Malden, MA), 2023-04, Vol.12 (7), p.8278-8288

2023

Link zum Volltext

Verfügbarkeit prüfen

Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers

Cancers, 2020-11, Vol.12 (11), p.3483

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens

Breast (Edinburgh), 2018-10, Vol.41, p.127-132

2018

Link zum Volltext

Verfügbarkeit prüfen

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2123-2127

2013

Link zum Volltext

Verfügbarkeit prüfen

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Frontiers in oncology, 2022-02, Vol.11, p.827625-827625

2022

Link zum Volltext

Verfügbarkeit prüfen

Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol

BMC health services research, 2018-07, Vol.18 (1), p.513-513, Article 513

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 197

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(190)
Mit Volltextzugriff
(178)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Life Sciences & Biomedicine
(117)
Humans
(97)
Female
(76)
Oncology
(71)
Middle Aged
(51)
Adult
(47)
Breast Cancer
(43)
Breast Neoplasms - Drug Therapy
(42)
Aged
(39)
Breast Neoplasms - Pathology
(32)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(26)
Male
(26)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(25)
Chemotherapy
(24)
Tumors
(23)
Biological And Medical Sciences
(21)
Treatment Outcome
(21)
Aged, 80 And Over
(20)
Medical Sciences
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

Breast cancer bone metastases: pathogenesis and therapeutic targets

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

HER2 positive metastatic breast cancer: What happens after first line failure?

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

The role of pigment epithelium-derived factor in protecting against cellular stress

NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Contralateral Breast Cancer: Influence Of Molecular Subtype, Clinical Features And Treatment Given In A Single Institution Study

Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial

Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Prognostic role of immune environment in luminal B early breast cancer

Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers

Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol

Suchergebnisse filtern